Would you recommend the following article to a politician, an athlete, a business executive, or a scientist?

UBS Global criticizes proposed Mylan-King deal WASHINGTON An investment firm has told Mylan Laboratories that a proposed acquisition of King Pharmaceuticals is not in the best interests of investors.
